PubRank

Sharon L Walmsley

Author PubWeight™ 41.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003 8.76
2 Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006 2.14
3 Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005 1.87
4 Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study. PLoS One 2009 1.87
5 Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis 2004 1.52
6 Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). CMAJ 2003 1.25
7 Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice. CMAJ 2003 1.25
8 No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS 2011 1.22
9 Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006 1.20
10 Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS 2010 1.14
11 Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc 2013 1.07
12 A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010 1.05
13 One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med 2007 0.96
14 A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS 2012 0.94
15 Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther 2004 0.92
16 TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007 0.90
17 Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis 2009 0.88
18 Treatment of HIV infection in pregnant women: antiretroviral management options. Drugs 2004 0.86
19 CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis 2005 0.85
20 Salvage antiretroviral therapy in HIV infection. Expert Opin Pharmacother 2002 0.84
21 Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med 2002 0.83
22 Inclusion body myositis: another possible manifestation of antiretroviral-associated mitochondrial toxicity. AIDS 2003 0.83
23 Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfected adults: an observational cohort study. BMJ Open 2014 0.82
24 Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm Res 2012 0.81
25 Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV. AIDS Res Hum Retroviruses 2014 0.80
26 Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial. Trials 2010 0.79
27 The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection? J Infect Dis 2012 0.79
28 The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada. AIDS Care 2013 0.79
29 Clinical problem-solving. Where are you from? N Engl J Med 2002 0.78
30 Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. Clin Infect Dis 2013 0.77
31 Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy. AIDS Res Hum Retroviruses 2012 0.77
32 Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. AIDS 2017 0.77
33 Management of persons infected with human immunodeficiency virus requiring admission to the intensive care unit. Crit Care Clin 2013 0.76
34 Response to Stegmann s, et Al. [J. Clin. Virol. 47 (1) (2010) 79-81]. J Clin Virol 2010 0.75
35 Raltegravir as antiretroviral therapy in HIV/AIDS. Expert Opin Pharmacother 2013 0.75
36 In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents. Pharm Res 2014 0.75
37 Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies. Clin Infect Dis 2002 0.75
38 Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen. HIV Clin Trials 2007 0.75
39 Lipodystrophy severity does not contribute to HAART nonadherence. AIDS Behav 2006 0.75